Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2025)

Entrada Therapeutics has reported EBITDA Margin over the past 3 years, most recently at 3012.55% for Q4 2025.

  • Quarterly results put EBITDA Margin at 3012.55% for Q4 2025, down 301286.0% from a year ago — trailing twelve months through Dec 2025 was 562.74% (down 59377.0% YoY), and the annual figure for FY2025 was 562.74%, down 59377.0%.
  • EBITDA Margin for Q4 2025 was 3012.55% at Entrada Therapeutics, down from 2720.76% in the prior quarter.
  • Over the last five years, EBITDA Margin for TRDA hit a ceiling of 82.25% in Q3 2023 and a floor of 3012.55% in Q4 2025.
  • Median EBITDA Margin over the past 3 years was 43.1% (2023), compared with a mean of 674.98%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 20272bps in 2024 and later plummeted -301286bps in 2025.
  • Entrada Therapeutics' EBITDA Margin stood at 21.16% in 2023, then surged by 101bps to 0.31% in 2024, then crashed by -971335bps to 3012.55% in 2025.
  • The last three reported values for EBITDA Margin were 3012.55% (Q4 2025), 2720.76% (Q3 2025), and 2212.31% (Q2 2025) per Business Quant data.